VERTEX PHARMACEUTICALS INC / MA (VRTX) Quick Ratio
- Quick ratio · latest quarter: Value 2.54×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 2.54× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $9.99B ÷ $3.94B ≈ 2.54× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 9.99B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 3.94B USD | Liabilities, Current |
| Cash and equivalents | 6.14B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 1.71B USD | Marketable Securities, Current · Available-for-sale Securities, Current |
| Customer receivables | 2.13B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 1.77B USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $9.99B | $3.94B | $6.14B | $1.71B | $2.13B | $1.77B | 2.54× |
| 2026-03-31 | $9.24B | $3.88B | $5.49B | $1.75B | $2.00B | $1.77B | 2.38× |
| 2025-12-31 | $8.66B | $3.86B | $5.08B | $1.52B | $2.05B | $1.69B | 2.24× |
| 2025-09-30 | $8.23B | $4.48B | $4.94B | $1.35B | $1.95B | $1.63B | 1.84× |
| 2025-06-30 | $8.28B | $4.14B | $4.97B | $1.41B | $1.89B | $1.50B | 2.00× |
| 2025-03-31 | $8.01B | $3.78B | $4.67B | $1.53B | $1.81B | $1.36B | 2.12× |
| 2024-12-31 | $7.73B | $3.56B | $4.57B | $1.55B | $1.61B | $1.21B | 2.17× |
| 2024-09-30 | $8.28B | $3.97B | $5.24B | $1.29B | $1.75B | $1.08B | 2.08× |
| 2024-06-30 | $7.45B | $3.55B | $4.58B | $1.22B | $1.66B | $914.60M | 2.10× |
| 2024-03-31 | $11.96B | $3.80B | $9.16B | $1.01B | $1.79B | $813.10M | 3.15× |
| 2023-12-31 | $12.78B | $3.55B | $10.37B | $849.20M | $1.56B | $738.80M | 3.60× |
| 2023-09-30 | $13.47B | $3.60B | $11.11B | $818.00M | $1.54B | $688.70M | 3.74× |
| 2023-06-30 | $12.79B | $3.35B | $10.15B | $1.09B | $1.56B | $603.50M | 3.82× |
| 2023-03-31 | $11.96B | $3.03B | $9.29B | $1.12B | $1.55B | $535.10M | 3.95× |
| 2022-12-31 | $12.22B | $2.74B | $10.50B | $274.50M | $1.44B | $460.60M | 4.46× |
| 2022-09-30 | $11.16B | $2.61B | $9.17B | $599.20M | $1.39B | $388.20M | 4.28× |
| 2022-06-30 | $10.59B | $2.56B | $8.70B | $551.20M | $1.33B | $367.70M | 4.14× |
| 2022-03-31 | $9.53B | $2.18B | $7.60B | $638.00M | $1.29B | $338.90M | 4.37× |
| 2021-12-31 | $8.66B | $2.14B | $6.79B | $729.90M | $1.14B | $353.10M | 4.04× |
| 2021-09-30 | $8.06B | $1.91B | $6.28B | $685.19M | $1.10B | $333.46M | 4.21× |
| 2021-06-30 | $7.64B | $1.84B | $6.06B | $644.32M | $929.14M | $321.62M | 4.16× |
| 2021-03-31 | $7.90B | $1.94B | $6.30B | $619.64M | $977.55M | $298.86M | 4.06× |
| 2020-12-31 | $7.54B | $1.88B | $5.99B | $670.71M | $885.35M | $280.78M | 4.02× |
| 2020-09-30 | $6.94B | $2.00B | $5.36B | $792.97M | $791.92M | $245.46M | 3.46× |
| 2020-06-30 | $6.24B | $1.80B | $4.83B | $619.44M | $791.77M | $219.22M | 3.47× |
| 2020-03-31 | $5.04B | $1.54B | $3.59B | $596.98M | $845.27M | $187.09M | 3.27× |
| 2019-12-31 | $4.44B | $1.33B | $3.11B | $698.97M | $633.52M | $167.50M | 3.33× |
| 2019-09-30 | $4.44B | $1.39B | $3.40B | $598.39M | $443.31M | $162.31M | 3.20× |
| 2019-06-30 | $4.42B | $1.26B | $3.29B | $656.54M | $464.90M | $143.02M | 3.51× |
| 2019-03-31 | $3.92B | $1.11B | $2.89B | $584.15M | $438.30M | $136.70M | 3.54× |
| 2018-12-31 | $3.58B | $1.12B | $2.65B | $518.11M | $409.69M | $124.36M | 3.19× |
| 2018-09-30 | $3.44B | $992.51M | $2.48B | $577.58M | $379.75M | $124.15M | 3.46× |
| 2018-06-30 | $3.16B | $927.30M | $2.15B | $622.40M | $393.44M | $115.03M | 3.41× |
| 2018-03-31 | $2.80B | $827.31M | $2.00B | $481.12M | $327.29M | $117.35M | 3.39× |
| 2018-01-01 | (m) | (m) | (m) | (m) | $311.22M | $111.74M | (m) |
| 2017-12-31 | $2.37B | $807.26M | $1.67B | $423.25M | $281.34M | $111.83M | 2.94× |
| 2017-09-30 | $2.08B | $710.74M | $1.38B | $427.28M | $263.49M | $98.19M | 2.92× |
| 2017-06-30 | $1.92B | $625.41M | $1.22B | $445.52M | $247.95M | $92.26M | 3.06× |
| 2017-03-31 | $1.62B | $489.80M | $1.00B | $405.10M | $207.96M | $82.02M | 3.30× |
| 2016-12-31 | $1.64B | $792.54M | $1.18B | $250.61M | $201.08M | $77.60M | 2.06× |
| 2016-09-30 | $1.31B | $722.84M | $719.69M | $408.75M | $182.23M | $71.80M | 1.81× |
| 2016-06-30 | $1.26B | $622.86M | $605.87M | $465.57M | $189.36M | $66.59M | 2.02× |
| 2016-03-31 | $1.21B | $552.04M | $604.25M | $421.37M | $181.88M | $63.20M | 2.19× |
| 2015-12-31 | $1.22B | $506.35M | $714.77M | $327.69M | $177.64M | $57.21M | 2.41× |
| 2015-09-30 | $1.17B | $374.96M | $756.25M | $249.58M | $165.27M | $49.20M | 3.12× |
| 2015-06-30 | $1.11B | $373.82M | $870.54M | $145.91M | $94.52M | $42.11M | 2.97× |
| 2015-03-31 | $1.26B | $302.44M | $664.88M | $516.25M | $80.33M | $34.09M | 4.17× |
| 2014-12-31 | $1.46B | $368.25M | $625.26M | $761.85M | $75.96M | $30.85M | 3.97× |
| 2014-09-30 | $1.59B | $372.18M | $718.56M | $759.17M | $114.31M | $16.75M | 4.28× |
| 2014-06-30 | $1.30B | $362.97M | $420.56M | $798.60M | $81.84M | $11.98M | 3.58× |
| 2014-03-31 | $1.38B | $373.50M | $424.05M | $900.15M | $59.86M | $11.26M | 3.71× |
| 2013-12-31 | $1.55B | $397.83M | $569.30M | $895.78M | $85.52M | $14.15M | 3.90× |
| 2013-09-30 | $1.54B | $409.50M | $583.18M | $839.47M | $120.28M | $13.54M | 3.77× |
| 2013-06-30 | $1.60B | $381.65M | $531.25M | $899.45M | $164.87M | $19.51M | 4.18× |
| 2013-03-31 | $1.43B | $407.64M | $379.10M | $860.25M | $194.05M | $21.53M | 3.52× |
| 2012-12-31 | $1.46B | $432.62M | $489.41M | $831.81M | $143.25M | $30.46M | 3.39× |
| 2012-09-30 | $1.44B | $406.73M | $436.89M | $861.66M | $139.63M | $86.28M | 3.54× |
| 2012-06-30 | $1.41B | $379.71M | $454.06M | $769.27M | $185.62M | $87.81M | 3.71× |
| 2012-03-31 | $1.21B | $356.81M | $267.92M | $712.94M | $232.23M | $129.59M | 3.40× |
| 2011-12-31 | $1.15B | $392.35M | $475.32M | $493.60M | $183.13M | $112.43M | 2.94× |
| 2011-09-30 | $1.10B | $548.95M | $542.54M | $116.14M | $445.66M | $67.65M | 2.01× |
| 2011-06-30 | $689.51M | $478.97M | $458.19M | $135.30M | $96.02M | $52.62M | 1.44× |
| 2011-03-31 | $829.05M | $416.19M | $446.54M | $376.92M | $5.59M | $17.82M | 1.99× |
| 2010-12-31 | $1.04B | $474.78M | $243.20M | $788.21M | $12.53M | (m) | 2.20× |
| 2010-09-30 | $1.21B | $311.57M | $569.90M | $633.11M | $4.96M | (m) | 3.88× |
| 2010-06-30 | $982.69M | $292.38M | $337.61M | $641.54M | $3.55M | (m) | 3.36× |
| 2010-03-31 | $1.10B | $211.54M | $396.55M | $696.14M | $7.88M | (m) | 5.20× |
| 2009-12-31 | $1.29B | $284.88M | $446.66M | $838.25M | $9.60M | (m) | 4.54× |
| 2009-09-30 | (m) | (m) | $559.13M | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | $408.95M | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | $602.20M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $389.12M | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $355.66M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |